LNAI.US Lunai Bioworks Inc.
- Market cap
- USD 830K
- P/E
- -
- P/B
- 0.48x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is LNAI.US undervalued?
Graham numberThe Graham number of Lunai Bioworks Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lunai Bioworks Inc. fundamental analysis
No fundamental analysis for Lunai Bioworks Inc. yet.
Lunai Bioworks Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lunai Bioworks Inc.
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States, Canada, and the Netherlands. It operates through two segments, RENB and BioSymetrics. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops BioSymetrics p…
Full company profileLunai Bioworks Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lunai Bioworks Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 52.0K | 124K |
| Gross Profit | -391K | - | 0.00 | 0.00 | -129K | -41.5K | 5.53K |
| Operating Income | -23.4M | -116M | -38.6M | -81.6M | -18.5M | -7.87M | -8.56M |
| EBITDA | -26.1M | -113M | -38.9M | -85.9M | -177M | -7.77M | -8.44M |
| Net Income | -26.7M | -113M | -39.7M | -88.4M | -178M | -3.56M | -8.04M |
| EPS | -45 | -173 | -56 | -73 | -86 | -1.06 | -1.74 |
| Balance Sheet | |||||||
| Total Assets | 190M | 84.6M | 58.3M | 163M | 8.23M | 9.94M | 9.94B |
| Total Liabilities | 14.9M | 12.0M | 11.8M | 31.2M | 29.6M | 19.0M | 19.0B |
| Shareholders' Equity | 175M | 72.6M | 46.5M | 132M | -21.3M | -9.02M | -9.02M |
| Cash & Short-term Investments | 20.7M | 9.17M | 1.87M | 220K | 481K | 1.71M | 1.71B |
| Total Debt | 7.37M | 7.02M | 5.59M | 3.79M | 10.2M | 1.34M | 1.34B |
| Cash Flow | |||||||
| Operating Cash Flow | -20.6M | -15.7M | -11.8M | -11.0M | -7.87M | -5.29B | -7.36M |
| Capital Expenditure | 48.9K | 5.16K | 29.8K | 70.4K | 3.00 | 1.24M | 0.00 |
| Free Cash Flow | -20.7M | -15.7M | -11.8M | -11.0M | -7.87M | -5.29B | -7.36M |
| Ratios | |||||||
| ROE | -15.3% | -156.2% | -85.3% | -67.0% | - | - | - |
| ROA | -14.1% | -134.0% | -68.1% | -54.2% | -2,162.7% | -35.8% | -0.1% |
| Net Profit Margin | - | - | - | - | - | -6,852.0% | -6,475.7% |
| Debt to Equity | 0.04x | 0.10x | 0.12x | 0.03x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lunai Bioworks Inc. dividends
Lunai Bioworks Inc. has not paid dividends in the last 6 fiscal years.
Last stock split: 1:8 on May 22, 2026.
Who owns Lunai Bioworks Inc.
- Insiders 37.48%
- Institutions 3.92%
- Public & others 58.60%
- Shares outstanding 5.03M
- Free float 4.23M
Top funds holding LNAI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 26.4K | 0.52% | -0.21% | Sep 2026 |
| Fidelity Total Market Index | 7.38K | 0.15% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 1.75K | 0.03% | 0.00% | Sep 2026 |
| Knights of Columbus U.S. All Cap Idx I | 23.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding LNAI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Ground Swell Capital, LLC | 53.2K | 1.17% | 0.00% | Jun 2026 |
| State Street Corp | 37.5K | 0.83% | +740.51% | Jun 2026 |
| Geode Capital Management, LLC | 24.2K | 0.53% | +6.04% | Jun 2026 |
| Jane Street Group LLC | 23.7K | 0.52% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 16.1K | 0.35% | +33.32% | Jun 2026 |
| BlackRock Inc | 15.9K | 0.35% | -0.05% | Jun 2026 |
| Virtu Financial LLC | 12.9K | 0.28% | +36.88% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 8.64K | 0.19% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 1.69K | 0.04% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 1.41K | 0.03% | +138.95% | Jun 2026 |
| Group One Trading, LLC | 544.00 | 0.01% | -0.18% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 326.00 | 0.01% | -0.31% | Jun 2026 |
| Compass Financial Management LLC | 125.00 | 0.00% | 0.00% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 24.00 | 0.00% | +20.00% | Jun 2026 |
| JPMorgan Chase & Co | 6.00 | 0.00% | -40.00% | Jun 2026 |
| Deutsche Bank AG | 1.00 | 0.00% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| International Assets Investment Management, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Northern Trust Corp | 0.00 | 0.00% | -100.00% | Jun 2026 |
| SIMPLEX TRADING, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Lunai Bioworks Inc. company profile
- Company name
- Lunai Bioworks Inc.
- Ticker
- LNAI.US
- Exchange
- USA Stocks
- Listed since
- Feb 2, 2015
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 12
- Fiscal year end
- June
- Address
- 3400 Cottage Way, Sacramento, CA, United States, 95825
- Phone
- (424) 222-9301
- Website
- lunaibioworks.com
About Lunai Bioworks Inc.
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States, Canada, and the Netherlands. It operates through two segments, RENB and BioSymetrics. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops BioSymetrics platform, for multi-omics integration for target identification and validation; clinical trial optimization, including patient stratification and response monitoring; and screening of gene and small molecule effects for the purpose of identifying novel drug targets and therapeutics. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is based in Sacramento, California.
Lunai Bioworks Inc. management
1- Mr. David H. WeinsteinCEO & Director · born 1961